Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. https://doi.org/10.3322/caac.21763.

Article  PubMed  Google Scholar 

Moreno C. Standard treatment approaches for relapsed/refractory chronic lymphocytic leukemia after frontline chemoimmunotherapy. Hematol Am Soc Hematol Educ Program. 2020;2020(1):33–40. https://doi.org/10.1182/hematology.2020000086.

Article  Google Scholar 

Woyach JA. Management of relapsed/refractory chronic lymphocytic leukemia. Am J Hematol. 2022;97(Suppl. 2):S11–8. https://doi.org/10.1002/ajh.26683.

Article  PubMed  PubMed Central  Google Scholar 

Raedler LA. Imbruvica (ibrutinib), first-in-class Bruton’s tyrosine kinase inhibitor, receives expanded indications for patients with relapsed chronic lymphocytic leukemia. Am Health Drug Benefits. 2015;8(Spec Future):66–9.

PubMed  PubMed Central  Google Scholar 

Munir T, Brown JR, O’Brien S, Barrientos JC, Barr PM, Reddy NM, et al. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94(12):1353–63. https://doi.org/10.1002/ajh.25638.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mato AR, Nabhan C, Thompson MC, Lamanna N, Brander DM, Hill B, et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica. 2018;103(5):874–9. https://doi.org/10.3324/haematol.2017.182907.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guo Y, Liu Y, Hu N, Yu D, Zhou C, Shi G, et al. Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton’s tyrosine kinase. J Med Chem. 2019;62(17):7923–40. https://doi.org/10.1021/acs.jmedchem.9b00687.

Article  CAS  PubMed  Google Scholar 

Brown JR, Eichhorst B, Hillmen P, Jurczak W, Kaźmierczak M, Lamanna N, et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2023;388(4):319–32. https://doi.org/10.1056/NEJMoa2211582.

Article  CAS  PubMed  Google Scholar 

Wierda WG, Brown J, Abramson JS, Awan F, Bilgrami SF, Bociek G, et al. NCCN Guidelines® insights: chronic lymphocytic leukemia/small lymphocytic lymphoma, Version 3.2022. J Natl Compr Canc Netw. 2022;20(6):622–34. https://doi.org/10.6004/jnccn.2022.0031.

Article  CAS  PubMed  Google Scholar 

Eichhorst B, Robak T, Montserrat E, Ghia P, Niemann CU, Kater AP, et al. Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(1):23–33. https://doi.org/10.1016/j.annonc.2020.09.019.

Article  CAS  PubMed  Google Scholar 

Chen Q, Jain N, Ayer T, Wierda WG, Flowers CR, et al. Economic burden of chronic lymphocytic leukemia in the era of oral targeted therapies in the United States. J Clin Oncol. 2017;35(2):166–74. https://doi.org/10.1200/JCO.2016.68.2856.

Article  CAS  PubMed  Google Scholar 

Mato AR, Thompson M, Allan JN, Brander DM, Pagel JM, Ujjani CS, et al. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica. 2018;103(9):1511–7. https://doi.org/10.3324/haematol.2018.193615.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Winqvist M, Asklid A, Andersson PO, Karlsson K, Karlsson C, Lauri B, et al. Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program: a study from the Swedish Chronic Lymphocytic Leukemia Group. Haematologica. 2016;101(12):1573–80. https://doi.org/10.3324/haematol.2016.144576.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abrisqueta P, Loscertales J, Terol MJ, Ramírez Payer Á, Ortiz M, Pérez I, et al. Real-world characteristics and outcome of patients treated with single-agent ibrutinib for chronic lymphocytic leukemia in Spain (IBRORS-LLC Study). Clin Lymphoma Myeloma Leuk. 2021;21(12):e985–99. https://doi.org/10.1016/j.clml.2021.07.022.

Article  CAS  PubMed  Google Scholar 

UK Cll Forum. Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients. Haematologica. 2016;101(12):1563–72. https://doi.org/10.3324/haematol.2016.147900.

Article  CAS  PubMed Central  Google Scholar 

Haacker M, Hallett TB, Atun R. On discount rates for economic evaluations in global health. Health Policy Plan. 2020;35(1):107–14. https://doi.org/10.1093/heapol/czz127.

Article  PubMed  Google Scholar 

Latimer N. NICE DSU technical support document 14: survival analysis for economic evaluations alongside clinical trials: extrapolation with patient-level data. 2011. https://www.ncbi.nlm.nih.gov/books/NBK395885/pdf/Bookshelf_NBK395885.pdf. Accessed 13 Aug 2023.

Mitchell M. Engauge digitizer software. http://markummitchell.github.io/engauge-digitizer. Accessed 28 Dec 2023.

Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9. https://doi.org/10.1186/1471-2288-12-9.

Article  PubMed  PubMed Central  Google Scholar 

R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https://www.R-project.org/. Accessed 28 Dec 2023.

Social Security. Actuarial life table. https://www.ssa.gov/oact/STATS/table4c6.html. Accessed 23 Aug 2023.

Lexicomp. https://www.wolterskluwer.com/en/solutions/lexicomp/lexicomp. Accessed 23 Apr 2023.

Alrawashdh N, McBride A, Erstad B, Sweasy J, Persky DO, Abraham I. Cost-effectiveness and economic burden analyses on all first-line treatments of chronic lymphocytic leukemia. Value Health. 2022;25(10):1685–95. https://doi.org/10.1016/j.jval.2022.04.001.

Article  PubMed  Google Scholar 

Reyes C, Engel-Nitz NM, DaCosta BS, Ravelo A, Ogale S, Bancroft T, et al. Cost of disease progression in patients with chronic lymphocytic leukemia, acute myeloid leukemia, and non-Hodgkin’s lymphoma. Oncologist. 2019;24(9):1219–28. https://doi.org/10.1634/theoncologist.2018-0019.

Article  PubMed  PubMed Central  Google Scholar 

Munir T, Genovez V, Genestier V, Ryan K, Liljas B, Gaitonde P. Cost-effectiveness of acalabrutinib regimens in treatment-naïve chronic lymphocytic leukemia in the United States. Expert Rev Pharmacoecon Outcomes Res. 2023;23(5):579–89. https://doi.org/10.1080/14737167.2023.2196408.

Article  PubMed  Google Scholar 

National Cancer Institute. Financial burden of cancer care. https://progressreport.cancer.gov/after/economic_burden. Accessed 25 Aug 2023.

Federal Reserve Economic Data. Consumer price index for all urban consumers: medical care in U.S. City average. https://fred.stlouisfed.org/series/CPIMEDSL. Accessed 23 Aug 2023.

National Institute for Health and Care Excellence. Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia. 2019. http://www.nice.org.uk/guidance/ta561. Accessed 29 Nov 2023.

Patel KK, Isufi I, Kothari S, Davidoff AJ, Gross CP, Huntington SF. Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia. Blood. 2020;136(17):1946–55. https://doi.org/10.1182/blood.2020004922.

Article  PubMed  Google Scholar 

Barnes JI, Divi V, Begaye A, Wong R, Coutre S, Owens DK, et al. Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p. Blood Adv. 2018;2(15):1946–56. https://doi.org/10.1182/bloodadvances.2017015461.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Neumann PJ, Kim DD. Cost-effectiveness thresholds used by study authors, 1990–2021. JAMA. 2023;329(15):1312–4. https://doi.org/10.1001/jama.2023.1792.

Article  PubMed  PubMed Central  Google Scholar 

Hatswell AJ, Bullement A, Briggs A, Paulden M, Stevenson MD. Probabilistic sensitivity analysis in cost-effectiveness models: determining model convergence in cohort models. Pharmacoeconomics. 2018;36(12):1421–6. https://doi.org/10.1007/s40273-018-0697-3.

Article  PubMed  Google Scholar 

National Cancer Institute. Cancer Stat Facts: leukemia: chronic lymphocytic leukemia (CLL). https://seer.cancer.gov/statfacts/html/clyl.html. Accessed 28 Nov 2023.

Barbier M, Durno N, Bennison C, Örtli M, Knapp C, Schwenkglenks M. Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland. Eur J Health Econ. 2022;23(5):837–46. https://doi.org/10.1007/s10198-021-01398-7.

Article  PubMed  Google Scholar 

Vemer P, Corro RI, van Voorn GA, Al MJ, Feenstra TL. AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users. Pharmacoeconomics. 2016;34(4):349–61. https://doi.org/10.1007/s40273-015-0327-2.

Article  CAS  PubMed  Google Scholar 

Vreman RA, Geenen JW, Hövels AM, Goettsch WG, Leufkens HGM, Al MJ. Phase I/II clinical trial-based early economic evaluation of acalabrutinib for relapsed chronic lymphocytic leukaemia. Appl Health Econ Health Policy. 2019;17(6):883–93. https://doi.org/10.1007/s40258-019-00496-1.

Article  PubMed  PubMed Central  Google Scholar 

Cull G, Burger JA, Opat S, Gottlieb D, Verner E, Trotman J, et al. Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study. Br J Haematol. 2022;196(5):1209–18. https://doi.org/10.1111/bjh.17994.

Article  CAS  PubMed  Google Scholar 

Byrd JC, Brown JR, O’Brien S, Barrientos JC, Kay NE, Reddy NM, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213–23. https://doi.org/10.1056/NEJMoa1400376.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517–28. https://doi.org/10.1056/NEJMoa1812836.

Article  CAS